BioWorld

Oct. 2, 2007

Adventrx Stock Falls 79% On CoFactor Trial Failure

The first clinical trial to directly compare Adventrx Pharmaceuticals Inc.'s CoFactor (ANX-510) to leucovorin missed its primary endpoint of reducing serious hematological or gastrointestinal adverse events associated with the chemotherapy drug 5-fluorouracil (5-FU).(BioWorld Today) Read More

Theratechnologies Reports Strong Results For TH9507

Frova Rejection By FDA Leaves Partners Annoyed

Pharmasset Starting Phase III Trial With Clevudine For HBV

House Passes Bill Called Vital to Free SBIR Money for Biotech

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

Financings Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...